JW THERAP-B (02126) announced that on May 19, 2026, the company, in accordance with the terms of the post-IPO incentive plan adopted on October 14, 2020, granted a total of 2 million share options to Mr. Tian Feng, the company's Executive Director and Chief Executive Officer.